Article
Podcast Interview: Chris Garabedian, CEO, AVI BioPharma
In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
